在早产婴儿和随后的喘息/喘中使用帕利维祖马布预防:为期10年的随访研究
Masahiko Kato1,2, Hiroyuki Mochizuki1,2, Yuichi Kama1
1Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan.
Pediatric pulmonology
|December 20, 2023
概括
在早产婴儿中使用帕利维祖马布的预防措施并不能防止到10岁时出现重复的喘息或喘. 孕产妇吸烟和对空气过敏原的敏感性与儿童喘的发展有关.
科学领域:
- 儿科呼吸系统医学 儿科呼吸系统医学
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 呼吸道同胞病毒 (RSV) 是导致婴儿喘息和喘的重要原因.
- 过早出生的婴儿有较高的RSV感染和随后的呼吸系统问题的风险.
- 了解RSV的长期影响及其预防对于儿童的呼吸系统健康至关重要.
研究的目的:
- 评估帕利维祖马布预防治疗在预防早产婴儿复发性喘息和喘方面的长期疗效.
- 评估帕利维祖马布在10岁时的影响,扩展之前的6年随访数据.
- 在这个队列中确定与喘发展相关的风险因素.
主要方法:
- 一项观察性,前性,多中心病例控制研究对早产婴儿 (33-35周怀孕) 进行了10年的跟踪.
- 在最初的RSV季节,Palivizumab的使用是基于标准的医疗实践.
- 通过基于手机的新型系统报告了医生诊断的复发性喘息/喘.
主要成果:
- 帕利维祖马布预防在10年内对复发性喘息或喘发病率没有显著差异.
- 母亲吸烟与空气过敏原敏感性相结合,与医生诊断的喘有显著的相关性.
- 在这个队列中,没有观察到palivizumab的长期显著益处.
结论:
- 在婴儿期服用帕利维祖马布的预防措施并没有防止到10岁时出现复发性喘息或喘发作.
- 母亲的被动吸烟和对空气过敏原的敏感性代表了儿童喘的重大风险因素.
- 需要进行进一步的研究,以探索针对RSV相关呼吸道疾病的有效预防策略.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:19Antiasthma Drugs: Leukotriene Modifiers
315
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
315
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
01:20Asthma: Pathogenesis and Management
411
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
411
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K